21:41 , Jul 25, 2019 |  BC Innovations  |  Emerging Company Profile

Axial: targeting gut microbe metabolites for CNS disorders

Microbiome play Axial is using small molecules to treat the gut end of the gut-brain axis for Parkinson's disease and autism. Co-founder and CEO David Donabedian told BioCentury that Axial Biotherapeutics Inc. believes that the...
00:09 , Jun 21, 2019 |  BC Extra  |  Financial News

June 20 Financial Quick Takes: Zymeworks raises $175M; plus Casdin, Scholar Rock and more

Zymeworks trades up after follow-on  Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) added $1.74 (10%) to $20.05 Thursday after raising $175 million late Wednesday through the sale of 9.7 million shares at $18 in a follow-on. The price...
21:03 , Jun 3, 2019 |  BC Extra  |  Preclinical News

June 3 Preclinical Quick Takes: 'CRISPR baby' gene mutation increases mortality; Axial's microbiome for autism

CCR5 mutation linked to increased death rate  Using genomic and health data from over 400,000 individuals in the UK Biobank, University of California Berkeley researchers found that homozygous Δ32 mutations in CC chemokine receptor 5...
01:00 , Mar 9, 2019 |  BioCentury  |  Finance

Seventure maps its microbiome future

Seventure Partners' second microbiome-based fund aims to foster a generation of companies beyond those focused only on live therapeutics. On March 5, the firm announced a first close of Health for Life Capital II, intended as...
14:36 , Mar 5, 2019 |  BC Extra  |  Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
00:47 , Mar 2, 2019 |  BC Extra  |  Company News

Emerging company roundup: Anthos, Maze, Oyster Point

In a week that had at least four companies post venture raises north of $80 million, Maze Therapeutics and Anthos Therapeutics Inc. had the biggest hauls, with financings near or above $200 million. Blackstone partnered...
20:08 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
13:00 , Feb 27, 2019 |  BC Extra  |  Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
22:55 , Oct 30, 2018 |  BC Extra  |  Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...
22:53 , Nov 3, 2017 |  BC Extra  |  Company News

Management tracks: Tissue Regenix, Therapix

Regenerative medical device company Tissue Regenix Group plc (LSE:TRX) named Steve Couldwell CEO. A Tissue Regenix director since 2013, Couldwell was COO of global biosurgery at Sanofi (Euronext:SAN; NYSE:SNY). Cannabinoid company Therapix Biosciences Ltd. (Tel...